 | • レポートコード：MRC2206A017 • 出版社/出版日：Persistence Market Research / 2022年3月29日 • レポート形態：英文、PDF、336ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートでは、世界の皮膚糸状菌性爪真菌症治療市場について広く調査・分析し、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症の影響分析、価格分析、市場規模分析・予測、治療別（治療薬、レーザー）分析、疾患別（遠位爪下爪真菌症、白色表在性爪真菌症、近位爪下爪真菌症、カンジダ爪真菌症、総ジストロフィー性爪真菌症）分析、性別（男性、女性）分析、年齢層別（0-18歳、18-39歳、40-64歳、65歳以上）分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しております。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症の影響分析 ・価格分析 ・市場規模分析・予測 ・世界の皮膚糸状菌性爪真菌症治療市場規模：治療別（治療薬、レーザー） ・世界の皮膚糸状菌性爪真菌症治療市場規模：疾患別（遠位爪下爪真菌症、白色表在性爪真菌症、近位爪下爪真菌症、カンジダ爪真菌症、総ジストロフィー性爪真菌症） ・世界の皮膚糸状菌性爪真菌症治療市場規模：性別（男性、女性） ・世界の皮膚糸状菌性爪真菌症治療市場規模：年齢層別（0-18歳、18-39歳、40-64歳、65歳以上） ・世界の皮膚糸状菌性爪真菌症治療市場規模：地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Dermatophytic Onychomycosis Therapeutics Market: Scope of Report
The latest publication by Persistence Market Research on the global dermatophytic onychomycosis therapeutics (DOT) market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2031.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for dermatophytic onychomycosis therapeutics products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the dermatophytic onychomycosis therapeutics market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the dermatophytic onychomycosis therapeutics market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the dermatophytic onychomycosis therapeutics market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the DOT market offers information divided into six important segments – treatment type, indication, gender, age group, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Treatment Type
Drugs
Oral
Rx
OTC
Topical
Rx
OTC
Lasers
C02 Ablative Lasers
Nd:YAG Lasers
Dual-wave Length Near-infrared Lasers
Photodynamic Therapy
Indication
Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Candidal Onychomycosis
Total Dystrophic Onychomycosis
Gender
Male
Female
Age Group
0-18 Years
18-39 Years
40-64 Years
65 Years and Above
Distribution Channel
Institutional Sales
Hospitals
Dermatology Clinics
Retail Sales
Retail Pharmacies
Drug Stores
Mail Order Pharmacies & Online Sales
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for dermatophytic onchomycosis therapeutics over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the dermatophytic onychomycosis therapeutics industry avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the (DOT market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research’s projections on the growth prospects of the dermatophytic onychomycosis therapeutics market are more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology
4.2. Treatment Regime (Prescription Pattern)
4.3. Key Regulation Scenario
4.4. Pipeline Analysis
4.5. Reimbursement Scenario
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Per Capita Healthcare Expenditure Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Social Determinants
5.2.2. Growing Elderly Population and future Outlook
5.2.3. New Market Development For Advanced Products Exhibit Lucrative Growth Opportunities
5.3. Value Chain
5.4. Market Dynamics
5.4.1. Drivers
5.4.2. Restraints
5.4.3. Opportunity Analysis
6. COVID19 – Impact Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.4.1. Revenue By Treatment
6.4.2. Revenue By Indication
6.4.3. Revenue By Gender
6.4.4. Revenue By Age Group
6.4.5. Revenue By Distribution Channel
6.4.6. Revenue By Country
6.5. Recovery Scenario – Short term, Midterm and Long Term Impact
7. Global Dermatophytic Onychomycosis Therapeutics Market – Pricing Analysis
7.1. Regional Pricing Analysis By Product
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Average Pricing Analysis Benchmark
8. Global Dermatophytic Onychomycosis Therapeutics Market (Size in US$ Mn) Analysis 2013-2021 and Forecast, 2022-2031
8.1. Historical Market Value (US$ Mn) Analysis, 2013-2021
8.2. Current and Future Market Value (US$ Mn) Projections, 2022-2031
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, By Treatment
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2013-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2022-2031
9.3.1. Drugs
9.3.1.1. Oral
9.3.1.1.1. Rx
9.3.1.1.2. OTC
9.3.1.2. Topical
9.3.1.2.1. Rx
9.3.1.2.2. OTC
9.3.2. Lasers
9.3.2.1. Neodymium: yttrium-aluminium-garnet laser (Nd:YAG)
9.3.2.2. Dual-wavelength near-infrared laser
9.3.2.3. CO2 Ablative Laser
9.3.3. Photodynamic Therapy
9.4. Market Attractiveness Analysis By Treatment
10. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) By Indication, 2013-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2031
10.3.1. Distal Subungual Onychomycosis
10.3.2. White Superficial Onychomycosis
10.3.3. Proximal Subungual Onychomycosis
10.3.4. Candida Onychomycosis
10.3.5. Total Dystrophic Onychomycosis
10.4. Market Attractiveness Analysis By Indication
11. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Gender
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Gender, 2013-2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Gender, 2022-2031
11.3.1. Male
11.3.2. Female
11.4. Market Attractiveness Analysis By Gender
12. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Age Group
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Age Group, 2013-2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Age Group, 2022-2031
12.3.1. 0-18 Years
12.3.2. 18-39 Years
12.3.3. 40-64 Years
12.3.4. 65 Years and Above
12.4. Market Attractiveness Analysis By Gender
13. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Distribution Channelbr /> 13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013-2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2031
13.3.1. Institutional Sales
13.3.1.1. Hospitals
13.3.1.2. Dermatology Clinics
13.3.2. Retail Sales
13.3.2.1. Retail Pharmacies
13.3.2.2. Drugs Stores
13.3.3. Mail Order Pharmacies & Online Sales
13.4. Market Attractiveness Analysis By Gender
14. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Region
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2013 – 2021
14.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 – 2031
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
15.3.1. By Country
15.3.1.1. U.S.
15.3.1.2. Canada
15.3.2. By Treatment
15.3.3. By Indication
15.3.4. By Gender
15.3.5. By Age group
15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
16. Latin America Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Treatment
16.3.3. By Indication
16.3.4. By Gender
16.3.5. By Age group
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants – Intensity Mapping
16.6. Drivers and Restraints – Impact Analysis
17. Europe Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. U.K.
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Rest of Europe
17.3.2. By Treatment
17.3.3. By Indication
17.3.4. By Gender
17.3.5. By Age group
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants – Intensity Mapping
17.6. Drivers and Restraints – Impact Analysis
18. South Asia Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Thailand
18.3.1.3. Indonesia
18.3.1.4. Malaysia
18.3.1.5. Rest of South Asia
18.3.2. By Treatment
18.3.3. By Indication
18.3.4. By Gender
18.3.5. By Age group
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Key Market Participants – Intensity Mapping
18.6. Drivers and Restraints – Impact Analysis
19. Oceania Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Treatment
19.3.3. By Indication
19.3.4. By Gender
19.3.5. By Age group
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.5. Key Market Participants – Intensity Mapping
19.6. Drivers and Restraints – Impact Analysis
20. Middle East and Africa Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Turkey
20.3.1.3. South Africa
20.3.1.4. Rest of Middle East and Africa
20.3.2. By Treatment
20.3.3. By Indication
20.3.4. By Gender
20.3.5. By Age group
20.3.6. By Distribution Channel
20.4. Market Attractiveness Analysis
20.5. Key Market Participants – Intensity Mapping
20.6. Drivers and Restraints – Impact Analysis
21. Key and Emerging Countries Dermatophytic Onychomycosis Therapeutics Market Analysis 2022 & 2031
21.1. Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. Dermatophytic Onychomycosis Therapeutics Market Analysis
21.2.1. By Treatment
21.2.2. By Indication
21.2.3. By Gender
21.2.4. By Age group
21.2.5. By Distribution Channel
21.3. Canada Dermatophytic Onychomycosis Therapeutics Market Analysis
21.3.1. By Treatment
21.3.2. By Indication
21.3.3. By Gender
21.3.4. By Age group
21.3.5. By Distribution Channel
21.4. Brazil Dermatophytic Onychomycosis Therapeutics Market Analysis
21.4.1. By Treatment
21.4.2. By Indication
21.4.3. By Gender
21.4.4. By Age group
21.4.5. By Distribution Channel
21.5. Mexico Dermatophytic Onychomycosis Therapeutics Market Analysis
21.5.1. By Treatment
21.5.2. By Indication
21.5.3. By Gender
21.5.4. By Age group
21.5.5. By Distribution Channel
21.6. Argentina Dermatophytic Onychomycosis Therapeutics Market Analysis
21.6.1. By Treatment
21.6.2. By Indication
21.6.3. By Gender
21.6.4. By Age group
21.6.5. By Distribution Channel
21.7. Germany Dermatophytic Onychomycosis Therapeutics Market Analysis
21.7.1. By Treatment
21.7.2. By Indication
21.7.3. By Gender
21.7.4. By Age group
21.7.5. By Distribution Channel
21.8. France Dermatophytic Onychomycosis Therapeutics Market Analysis
21.8.1. By Treatment
21.8.2. By Indication
21.8.3. By Gender
21.8.4. By Age group
21.8.5. By Distribution Channel
21.9. U.K. Dermatophytic Onychomycosis Therapeutics Market Analysis
21.9.1. By Treatment
21.9.2. By Indication
21.9.3. By Gender
21.9.4. By Age group
21.9.5. By Distribution Channel
21.10. Spain Dermatophytic Onychomycosis Therapeutics Market Analysis
21.10.1. By Treatment
21.10.2. By Indication
21.10.3. By Gender
21.10.4. By Age group
21.10.5. By Distribution Channel
21.11. BENELUX Dermatophytic Onychomycosis Therapeutics Market Analysis
21.11.1. By Treatment
21.11.2. By Indication
21.11.3. By Gender
21.11.4. By Age group
21.11.5. By Distribution Channel
21.12. Russia Dermatophytic Onychomycosis Therapeutics Market Analysis
21.12.1. By Treatment
21.12.2. By Indication
21.12.3. By Gender
21.12.4. By Age group
21.12.5. By Distribution Channel
21.13. India Dermatophytic Onychomycosis Therapeutics Market Analysis
21.13.1. By Treatment
21.13.2. By Indication
21.13.3. By Gender
21.13.4. By Age group
21.13.5. By Distribution Channel
21.14. Thailand Dermatophytic Onychomycosis Therapeutics Market Analysis
21.14.1. By Treatment
21.14.2. By Indication
21.14.3. By Gender
21.14.4. By Age group
21.14.5. By Distribution Channel
21.15. Indonesia Dermatophytic Onychomycosis Therapeutics Market Analysis
21.15.1. By Treatment
21.15.2. By Indication
21.15.3. By Gender
21.15.4. By Age group
21.15.5. By Distribution Channel
21.16. Malaysia Dermatophytic Onychomycosis Therapeutics Market Analysis
21.16.1. By Treatment
21.16.2. By Indication
21.16.3. By Gender
21.16.4. By Age group
21.16.5. By Distribution Channel
21.17. ASEAN Dermatophytic Onychomycosis Therapeutics Market Analysis
21.17.1. By Treatment
21.17.2. By Indication
21.17.3. By Gender
21.17.4. By Age group
21.17.5. By Distribution Channel
21.18. China Dermatophytic Onychomycosis Therapeutics Market Analysis
21.18.1. By Treatment
21.18.2. By Indication
21.18.3. By Gender
21.18.4. By Age group
21.18.5. By Distribution Channel
21.19. Japan Dermatophytic Onychomycosis Therapeutics Market Analysis
21.19.1. By Treatment
21.19.2. By Indication
21.19.3. By Gender
21.19.4. By Age group
21.19.5. By Distribution Channel
21.20. South Korea Dermatophytic Onychomycosis Therapeutics Market Analysis
21.20.1. By Treatment
21.20.2. By Indication
21.20.3. By Gender
21.20.4. By Age group
21.20.5. By Distribution Channel
21.21. Australia Dermatophytic Onychomycosis Therapeutics Market Analysis
21.21.1. By Treatment
21.21.2. By Indication
21.21.3. By Gender
21.21.4. By Age group
21.21.5. By Distribution Channel
21.22. New Zealand Dermatophytic Onychomycosis Therapeutics Market Analysis
21.22.1. By Treatment
21.22.2. By Indication
21.22.3. By Gender
21.22.4. By Age group
21.22.5. By Distribution Channel
21.23. GCC Countries Dermatophytic Onychomycosis Therapeutics Market Analysis
21.23.1. By Treatment
21.23.2. By Indication
21.23.3. By Gender
21.23.4. By Age group
21.23.5. By Distribution Channel
21.24. South Africa Dermatophytic Onychomycosis Therapeutics Market Analysis
21.24.1. By Treatment
21.24.2. By Indication
21.24.3. By Gender
21.24.4. By Age group
21.24.5. By Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
22.4.1. By Regional footprint of Players
22.4.2. Product foot print by Players
22.4.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Bausch Health
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Profitability by Market Segments (Product/Channel/Region)
23.3.1.4. Sales Footprint
23.3.1.5. Strategy Overview
23.3.1.5.1. Marketing Strategy
23.3.1.5.2. Product Strategy
23.3.1.5.3. Channel Strategy
23.3.2. Galderma S.A.
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Profitability by Market Segments (Product/Channel/Region)
23.3.2.4. Sales Footprint
23.3.2.5. Strategy Overview
23.3.2.5.1. Marketing Strategy
23.3.2.5.2. Product Strategy
23.3.2.5.3. Channel Strategy
23.3.3. Novartis AG
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Profitability by Market Segments (Product/Channel/Region)
23.3.3.4. Sales Footprint
23.3.3.5. Strategy Overview
23.3.3.5.1. Marketing Strategy
23.3.3.5.2. Product Strategy
23.3.3.5.3. Channel Strategy
23.3.4. Pfizer, Inc.
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Profitability by Market Segments (Product/Channel/Region)
23.3.4.4. Sales Footprint
23.3.4.5. Strategy Overview
23.3.4.5.1. Marketing Strategy
23.3.4.5.2. Product Strategy
23.3.4.5.3. Channel Strategy
23.3.5. Moberg Pharma AB
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Profitability by Market Segments (Product/Channel/Region)
23.3.5.4. Sales Footprint
23.3.5.5. Strategy Overview
23.3.5.5.1. Marketing Strategy
23.3.5.5.2. Product Strategy
23.3.5.5.3. Channel Strategy
23.3.6. Bayer AG
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Profitability by Market Segments (Product/Channel/Region)
23.3.6.4. Sales Footprint
23.3.6.5. Strategy Overview
23.3.6.5.1. Marketing Strategy
23.3.6.5.2. Product Strategy
23.3.6.5.3. Channel Strategy
23.3.7. Dr. Reddy’s Laboratories Ltd.
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Profitability by Market Segments (Product/Channel/Region)
23.3.7.4. Sales Footprint
23.3.7.5. Strategy Overview
23.3.7.5.1. Marketing Strategy
23.3.7.5.2. Product Strategy
23.3.7.5.3. Channel Strategy
23.3.8. Cipla Ltd.
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Profitability by Market Segments (Product/Channel/Region)
23.3.8.4. Sales Footprint
23.3.8.5. Strategy Overview
23.3.8.5.1. Marketing Strategy
23.3.8.5.2. Product Strategy
23.3.8.5.3. Channel Strategy
23.3.9. Medimetriks Pharmaceuticals, Inc.
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Profitability by Market Segments (Product/Channel/Region)
23.3.9.4. Sales Footprint
23.3.9.5. Strategy Overview
23.3.9.5.1. Marketing Strategy
23.3.9.5.2. Product Strategy
23.3.9.5.3. Channel Strategy
23.3.10. Sanofi S.A.
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Profitability by Market Segments (Product/Channel/Region)
23.3.10.4. Sales Footprint
23.3.10.5. Strategy Overview
23.3.10.5.1. Marketing Strategy
23.3.10.5.2. Product Strategy
23.3.10.5.3. Channel Strategy
23.3.11. GlaxoSmithKline Plc.
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Profitability by Market Segments (Product/Channel/Region)
23.3.11.4. Sales Footprint
23.3.11.5. Strategy Overview
23.3.11.5.1. Marketing Strategy
23.3.11.5.2. Product Strategy
23.3.11.5.3. Channel Strategy
23.3.12. Teva Pharmaceutical industries Ltd.
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Profitability by Market Segments (Product/Channel/Region)
23.3.12.4. Sales Footprint
23.3.12.5. Strategy Overview
23.3.12.5.1. Marketing Strategy
23.3.12.5.2. Product Strategy
23.3.12.5.3. Channel Strategy
23.3.13. Cardinal Health Inc.
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Profitability by Market Segments (Product/Channel/Region)
23.3.13.4. Sales Footprint
23.3.13.5. Strategy Overview
23.3.13.5.1. Marketing Strategy
23.3.13.5.2. Product Strategy
23.3.13.5.3. Channel Strategy
23.3.14. Viatris Inc.
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Profitability by Market Segments (Product/Channel/Region)
23.3.14.4. Sales Footprint
23.3.14.5. Strategy Overview
23.3.14.5.1. Marketing Strategy
23.3.14.5.2. Product Strategy
23.3.14.5.3. Channel Strategy
23.3.15. Almirall, S.A
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Profitability by Market Segments (Product/Channel/Region)
23.3.15.4. Sales Footprint
23.3.15.5. Strategy Overview
23.3.15.5.1. Marketing Strategy
23.3.15.5.2. Product Strategy
23.3.15.5.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Table 01: Reimbursement Analysis for OnychomycosisTable 02: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 03: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 04: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 05: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 06: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 07: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Region
Table 08: North America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 09: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 10: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 11: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 12: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 13: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 14: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 15: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 16: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 17: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 18: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 19: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 20: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 21: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 22: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 23: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 24: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 25: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 26: South Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 27: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 28: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 29: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 30: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 31: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 32: East Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 33: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 34: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 35: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 36: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 37: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 38: Oceania Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 39: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 40: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 41: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 42: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 43: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 44: MEA Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 45: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 46: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 47: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 48: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 49: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel